Log In
BCIQ
Print this Print this
 

Tyroserleutide (CMS024)

  Manage Alerts
Collapse Summary General Information
Company China Medical System Holdings Ltd.
DescriptionTripeptide compound
Molecular Target
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase III
Standard IndicationLiver cancer
Indication DetailsTreat unresectable primary liver cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today